These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 31114029)
1. Metastatic melanoma and immunotherapy-related uveitis: an incidence in Northern Ireland. Dolaghan MJ; Oladipo B; Cooke CA; McAvoy CE Eye (Lond); 2019 Oct; 33(10):1670-1672. PubMed ID: 31114029 [No Abstract] [Full Text] [Related]
2. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report. Numata S; Iwata Y; Okumura R; Arima M; Kobayashi T; Watanabe S; Suzuki K; Horiguchi M; Sugiura K J Dermatol; 2018 Jan; 45(1):113-114. PubMed ID: 28225147 [No Abstract] [Full Text] [Related]
3. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma. Reid G; Lorigan P; Heimann H; Hovan M Ocul Immunol Inflamm; 2019; 27(6):1012-1015. PubMed ID: 29672247 [No Abstract] [Full Text] [Related]
4. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553 [TBL] [Abstract][Full Text] [Related]
5. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma]. Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801 [TBL] [Abstract][Full Text] [Related]
6. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia. Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473 [No Abstract] [Full Text] [Related]
7. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma. Lasocki A; Smith K J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in colorectal cancer with mismatch repair deficiency. Overman MJ Clin Adv Hematol Oncol; 2019 May; 17(5):265-267. PubMed ID: 31188802 [No Abstract] [Full Text] [Related]
9. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. Alnabulsi R; Hussain A; DeAngelis D Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409 [TBL] [Abstract][Full Text] [Related]
10. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma. Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986 [TBL] [Abstract][Full Text] [Related]
11. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy. Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384 [No Abstract] [Full Text] [Related]
12. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab. Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767 [No Abstract] [Full Text] [Related]
13. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab. Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534 [No Abstract] [Full Text] [Related]
14. Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology. Tabata MM; Choi S; Hirotsu K; Kwong B; Soleymani T J Am Acad Dermatol; 2020 Apr; 82(4):986-994. PubMed ID: 31437546 [No Abstract] [Full Text] [Related]
15. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae. Donaldson M; Owen JL; Choi JN JAMA Dermatol; 2018 Jul; 154(7):846-847. PubMed ID: 29800007 [No Abstract] [Full Text] [Related]
16. Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases. Zieman D; Frankel AE J Immunother; 2019 Oct; 42(8):318-320. PubMed ID: 31318723 [TBL] [Abstract][Full Text] [Related]
17. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment. Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556 [No Abstract] [Full Text] [Related]
18. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab. Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688 [TBL] [Abstract][Full Text] [Related]
19. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675 [TBL] [Abstract][Full Text] [Related]
20. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]